Colforsin

For research use only. Not for use in humans.

製品コードS2449 別名:Forskolin, HL 362, Coleonol

Colforsin 化学構造

CAS No. 66575-29-9

Colforsin (Forskolin, HL 362, Coleonol) is a ubiquitous activator of eukaryotic adenylyl cyclase (AC) in a wide variety of cell types, commonly used to raise levels of cAMP in the study and research of cell physiology. Forskolin also activates PXR and FXR activity. Forskolin stimulates autophagy.

サイズ 価格(税別)  
JPY 20200
JPY 46800
JPY 63400
JPY 96600
最寄りの販売代理店を探す

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください:[email protected]

バルク問合せ

文献中Selleckの製品使用例(111)

製品安全説明書

cAMP阻害剤の選択性比較

生物活性

製品説明 Colforsin (Forskolin, HL 362, Coleonol) is a ubiquitous activator of eukaryotic adenylyl cyclase (AC) in a wide variety of cell types, commonly used to raise levels of cAMP in the study and research of cell physiology. Forskolin also activates PXR and FXR activity. Forskolin stimulates autophagy.
ターゲット
Adenylyl cyclase (AC) [1]
(A wide variety of cell types)
体外試験

Forskolin increases cAMP levels in preparations of membranes, cells, or tissues. Forskolin not only activates AC but also interacts with certain other proteins, including glucose transporters and ion channels. Forskolin is able to promote activation of nine different transmembrane iso-forms of AC, albeit with somewhat less efficacy for AC9, which could be used to provides a means to identify and quantify high-affinity binding sites, i.e., G-proteins (Gs)–AC complexes. Activation of s by GPCRs contributes to Forskolin-stimulated cAMP generation in cells because of s-Forskolin potentiation of AC activity. [1] Forskolin stimulates adenylate cyclase activity without interacting with cell surface receptors. Forskolin's potentiation of cAMP in turn inhibits basophil and mast cell degranulation and histamine release, lowers blood pressure and intraocular pressure, inhibits platelet aggregation, promotes vasodilation, bronchodilation, and thyroid hormone secretion, and stimulates lipolysis in fat cells. Forskolin inhibits the binding of platelet-activating factor (PAF), independently of cAMP formation, which may be a result of Forskolin's direct effect on PAF or via interference with PAF binding to receptor sites. Forskolin also appears to have an effect on several membrane transport proteins, and inhibits glucose transport in erythrocytes, adipocytes, platelets, and other cells. Forskolin is used to treat with glaucoma. [2]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT-29  NHjpWlZCeG:ydH;zbZMhSXO|YYm= MWW0NOKh|ryP NYLQTmpNPDkEoHi= NGHnU21FVVOR Ml7ybY5lfWOnczDjbIFv\2W|IHnuJJRp\SCyaH;zdIhwenmuYYTpc44he3SjdIXzJI9nKFCSMlGgeIFz\2W2cx?= MnHEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7OUe0OVEoRjJ2OUm3OFUyRC:jPh?=
SW480 MUDBdI9xfG:|aYOgRZN{[Xl? NVztTXIxPDEEoN88US=> MoPUOFjDqGh? MnfBSG1UVw>? MnPMbY5lfWOnczDjbIFv\2W|IHnuJJRp\SCyaH;zdIhwenmuYYTpc44he3SjdIXzJI9nKFCSMlGgeIFz\2W2cx?= NFPOS4s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm5O|Q2OSd-MkS5PVc1PTF:L3G+
HT-29  NXPMfGVjSXCxcITvd4l{KEG|c3H5 M2PiWFQxyqEQvF2= M1n2XFQ5yqCq MoXHSG1UVw>? MX7pcoR2[2W|IHHuJIFkfGm4YYTpc44hd2ZiY3HzdIF{\SB|L{e= MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl7N{S1NUc,OjR7OUe0OVE9N2F-
SW480 M3\DSGFxd3C2b4Ppd{BCe3OjeR?= NWLoRVZ7PDEEoN88US=> NUPmS2p5PDkEoHi= MVPEUXNQ NF3KbFZqdmS3Y3XzJIFvKGGldHn2ZZRqd25ib3[gZ4F{eGG|ZTCzM|c> MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl7N{S1NUc,OjR7OUe0OVE9N2F-
HT-29  Ml7pSpVv[3Srb36gRZN{[Xl? NETmdo01OMLizszN MUe3JIQ> NVfvPGZLTE2VTx?= M3vHfpJm\HWlZYOgZ49td26xc4Do[ZJmKG[xcn3heIlwdiClYYDhZoltcXS7wrC= MnnwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7OUe0OVEoRjJ2OUm3OFUyRC:jPh?=
SW480 M3zFZmZ2dmO2aX;uJGF{e2G7 MWK0NOKh|ryP MlzxO{Bl MojwSG1UVw>? MXjy[YR2[2W|IHPvcI9vd3OyaHXy[UBnd3KvYYTpc44h[2GyYXLpcIl1gcLi MlGxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7OUe0OVEoRjJ2OUm3OFUyRC:jPh?=
HT-29  NGPnTohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLmUYZ{PDEEoN88US=> NInQe|AxNTd{IHi= NGjlVXFFVVOR MVXpcohq[mm2czDj[YxtKGe{b4f0bEB1cW2nIHTldIVv\GWwdHz5 NWjDeY5vRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5PVc1PTFpPkK0PVk4PDVzPD;hQi=>
SW480 M1vMN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH6xWoo1OMLizszN NVfjPYlrOC15MjDo MXTEUXNQ M4m0S4lvcGmkaYTzJINmdGxiZ4Lve5RpKHSrbXWg[IVx\W6mZX70cJk> NYXJO2VURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5PVc1PTFpPkK0PVk4PDVzPD;hQi=>
HT-29  MV\GeY5kfGmxbjDBd5NigQ>? NVvqWnJxPDEEoN88US=> M1iwO|Q5yqCq NETKOYRFVVOR M13mS4FkfGm4YYTld{BRWDKD NGDYW5I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm5O|Q2OSd-MkS5PVc1PTF:L3G+
SW480 M1G5W2Z2dmO2aX;uJGF{e2G7 M4G2TFQxyqEQvF2= M3v3W|Q5yqCq MWHEUXNQ M{G0VIFkfGm4YYTld{BRWDKD NU\aOWlORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5PVc1PTFpPkK0PVk4PDVzPD;hQi=>
C6 NXy2PGRxTnWwY4Tpc44hSXO|YYm= MV2xNEDPxE4EoB?= M{DhclIxKG2rbh?= MXjpcoNz\WG|ZYOgZ2FOWCCjY3P1cZVt[XSrb36= M1TH[|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3ME[5OFE4Lz5{NUC2PVQyPzxxYU6=
Huh-7 Mo\lSpVv[3Srb36gRZN{[Xl? NUTuVJM{OC1{MDFOwG0> NGDoXZAzKGkEoB?= NYHUeIxXemW|dXz0d{BqdiCjIHTvd4Uu\GWyZX7k[Y51KGmwY4LlZZNmKGmwIHOtUZlkKGW6cILld5Nqd25iYYSgeIhmKHC{b4TlbY4h[W6mIH3SUmEhdGW4ZXzz M4fUPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUC5PFM1Lz5{NUGwPVg{PDxxYU6=
THP-1  M1;PNWZ2dmO2aX;uJGF{e2G7 NH\1UWYyNzFyIN88US=> MoXsNuKhcA>? M{ezbWROW00EoB?= MXTzeZBxemW|c3XzJG1EWC1zIIDyc4R2[3Srb39CpC=> NXjyT3pLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxOVQ5QDJpPkK1NVU1QDh{PD;hQi=>
BeWo  M{P1XWZ2dmO2aX;uJGF{e2G7 Ml3mNlAhyrWP NWLMPGJqPDhiaB?= MWfEUXNQyqB? NFS0N5RqdmS3Y3XzJINmdGxiZoXzbY9v NE\YZWc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUG4OFQ4Pyd-MkWxPFQ1Pzd:L3G+
ventricular cardiomyocytes  NVLkZYtWTnWwY4Tpc44hSXO|YYm= NWLr[FBsOC5yMT2xNEDPxE1? M1vXT4V3d2unczDhckBqdm:2cn;wbYMhemW|cH;ud4UhOTJywsGxOUUh[WKxdnWgZoF{[Wxid3n0bEBidiCHQ{WwxsBw\iB{LkKgxtVO MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJyM{GxN{c,OjV{MEOxNVM9N2F-
ventricular cardiomyocytes  NUC5Zot[TnWwY4Tpc44hSXO|YYm= NInDXGsxNjBzLUGwJO69VQ>? NVjONlJocW6lcnXhd4V{KCClQV3QJIFk[3WvdXzheIlwdg>? MnHWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{MEOxNVMoRjJ3MkCzNVE{RC:jPh?=
MIN6  M4\aOmZ2dmO2aX;uJGF{e2G7 M{HwZVExKM7:TdMg NFXDd5I{KGh? M4fWbIlv[3KnYYPld{BFOyCvUl7BJIV5eHKnc4Ppc44> NXvlfWg4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyOFEyOjRpPkK1NlQyOTJ2PD;hQi=>
L6 NVOwNZR2TnWwY4Tpc44hSXO|YYm= MYi0NEDDvU1? MorCNlQhcA>? NWe5VHhmcW6qaXLpeJMhTE2KMT3pcoR2[2WmIFHreEBi[3SrdnH0bY9v Ml7QQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{NEe1OVAoRjJ3MkS3OVUxRC:jPh?=
HEK‐CFTR MYfGeY5kfGmxbjDBd5NigQ>? NXL5NoljOuLCk{WwxsDPxE1? NIj4Z5IxNTF{IH3pci=> MVzEUXNQyqB? NHnGfIlqdmS3Y3XzJIEh\G:|ZfMAlIRmeGWwZHXueEBqd2SrZHWg[YZndHW6wrC= M{jad|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mk[zNlA4Lz5{NUK2N|IxPzxxYU6=
SK-N-SH MXPD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NFOyenIyOCEQvF5CpC=> NUTw[pR3PDhiaB?= MlnN[Y5p[W6lZYOgV2suVi2VSDDu[ZVzd2KuYYP0c41iKGOnbHygeoli[mmuaYT5 NIHpSnE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK2OlA3Oyd-MkWyOlYxPjN:L3G+
SK-N-AS  NEjmSnpHfW6ldHnvckBCe3OjeR?= MlHGNVAh|ryPwrC= MVKxNE8{OC94MDDtbY4> NXexOIg5cW6lcnXhd4V{KGyndnXsd{Bw\iCyLd8yMYNifGWwaX6gLJNmejZ5NTmgZY5lKGmwZIXj[ZMh[WOldX31cIF1cW:wIH;mJJAu|rJvY3H0[Y5qdiBqc3XyOlc2MSCrbjCodIVzcSmwdXPs[YFzKHKnZ3nvcpM> NXXJVml1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyOlYxPjNpPkK1NlY3ODZ|PD;hQi=>
SK-N-AS  NGnUdYxHfW6ldHnvckBCe3OjeR?= NUPOOnFPOTBizszNxsA> NYLMSY1POzBibXnu MVPpcoR2[2W|IIDoc5NxcG:{eXzheIlwdiCxZjFOtk1k[XSnbnnuJEh{\XJ4N{WpMEBxNUeVS{ROtkApe2W{OTmgZY5lKGOxbnPvcYl1[W62IHjp[4hmeiCuZY\lcJMhd2ZiYXP0bZZmNCC3boDoc5NxcG:{eXzheIVlNCEQsj3jZZRmdmmw MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ4NkC2N{c,OjV{Nk[wOlM9N2F-
SK-N-AS  NFLjUlZHfW6ldHnvckBCe3OjeR?= NVy5N5dvOTBizszNxsA> NEm0UFYzPCCq NEDVRZRqdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4Yh[3mlbHnuJGQy MnraQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{Nk[wOlMoRjJ3Mk[2NFY{RC:jPh?=
SK-N-AS  MYjGeY5kfGmxbjDBd5NigQ>? NVT6foFZOTBizszNxsA> MXiyOEBp MX7pcoNz\WG|ZYOgeIhmKGODTWCgcIV3\Wy|wrC= MlHGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{Nk[wOlMoRjJ3Mk[2NFY{RC:jPh?=
SK-N-AS  NFTXTHVE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NVf0[JJUOTBizszNxsA> M{jHUlI1NzR6IHi= NIPifFBmdmijbnPld{B1cW2nLXTldIVv\GWwdHz5JINmdGy3bHHyJJZq[WKrbHn0feKh M2rzWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mk[2NFY{Lz5{NUK2OlA3OzxxYU6=
granulosa cells NYDZ[mZpTnWwY4Tpc44hSXO|YYm= MX6xNEDPxE1? M3TnSFI1KGh? M3TPSolv[3KnYYPld{B1cGVibHX2[Yx{KG:oIGLHV|IheHKxbX;0[ZIh[WO2aY\peJk> M1jTZ|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{O5NVA2Lz5{NUOzPVExPTxxYU6=
granulosa cells NGX2SFRHfW6ldHnvckBCe3OjeR?= M17WV|ExKM7:TR?= NIS2eI4zPCCq Mn\ZbY5kemWjc3XzJJRp\SCrboTlcpNqfHlib3[gSG5CN3C{b4TlbY4h[2:vcHzlfC=> NHq1VGM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUOzPVExPSd-MkWzN|kyODV:L3G+
granulosa cells MYTGeY5kfGmxbjDBd5NigQ>? Mk\mNVAh|ryP M1\jcFEzNzJ2IHi= M1PGcIlv[3KnYYPld{B1cGVibHX2[Yx{KG:oIILldI9zfGW{IHHjeIl3cXS7IH\vdkB1cGVibH;u[4V{fCCocnHncYVvfCBq4pkSPFU1NytzOGLHV|IvVFWFKR?= NHi2SWk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUOzPVExPSd-MkWzN|kyODV:L3G+
granulosa cells NVruTm13TnWwY4Tpc44hSXO|YYm= MkPKNVAh|ryP MoDkNVIwOjRiaB?= MmnqbY5kemWjc3XzJJRp\SCuZY\lcJMhd2cEoGLHV|LDqG2UTlG= NXu1NXRVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzN|kyODVpPkK1N|M6OTB3PD;hQi=>
BeWo  NULXNY9{TnWwY4Tpc44hSXO|YYm= NGHE[2MzOMLiwsXN MXG0POKhcMLi M33UdmROW00EoB?= M{fOc4Rwf26{ZXf1cIF1\XNidHjlJIxmfmWuIH;mJGdEVS1z MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTN4MkK2NEc,OjV|NkKyOlA9N2F-
BeWo  NF3KWXpHfW6ldHnvckBCe3OjeR?= NHPndWIzOMLiwsXN MUK0POKhcMLi NULuRm1kTE2VT9Mg NGnNdY5ld3ewcnXneYxifGW|IITo[UBt\X[nbDDv[kBVVUWPRkG2 MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTN4MkK2NEc,OjV|NkKyOlA9N2F-
BeWo  Mlr6SpVv[3Srb36gRZN{[Xl? M3PET|IxyqEEtV2= MmDwOFjDqGkEoB?= M2rpSGROW00EoB?= MWPpcoNz\WG|ZYOgeIhmKGKndHGtbGNIKHKnbHXhd4U> NEfQOHU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUO2NlI3OCd-MkWzOlIzPjB:L3G+
EM1  MoXnSpVv[3Srb36gRZN{[Xl? NFfnVnQyPeLCit88US=> NEHiZYw1QCCq NUTpRppEemWmdXPld{B1cGViZYjwdoV{e2mxbjDv[uKhVEmIwrDvduKhWFSJU{NCpIlvyqCFQVzSMUBwesLiRWDBR|Iue2muZX7j[YQhTU1zIHPlcIx{yqB? MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTN5OE[2NUc,OjV|N{i2OlE9N2F-
Primary bovine chondrocytes MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYO1{txO MYm0PEBp MlHWdoV3\XK|ZYOgeIhmKGmwaHnibZRwenliZX\m[YN1KG:oIHPlcIVkd3irYjDvckBxem:uaX\ldoF1cW:wIHnuJIdzd3e2aDDwcIF1\SClaH;u[JJw[3m2ZYO= MmDPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2ME[wNVYoRjJ3NEC2NFE3RC:jPh?=
RBMECs NEm2UmdHfW6ldHnvckBCe3OjeR?= MnXLOeKh|ryP NFrufZcyKGh? MXficI9kc3NidHjlJIFkfGmwIHP5eI9{c2WuZYTvckBz\WG{cnHu[4Vu\W62IIPl[Y4hf2m2aDDFUWFRNUmLIITy[YF1dWWwdNMg MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTRzNk[1NUc,OjV2MU[2OVE9N2F-
RBMECs M17OTWZ2dmO2aX;uJGF{e2G7 NXH2T3pmPcLizszN NEjCTHkyKGh? MWLicI9kc3NidHjlJGVOSVBvSVmtbY5lfWOnZDDjbIFv\2ViaX6gUWxEKHCqb4PwbI9zgWyjdHnvci=> NX\pemVDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0NVY3PTFpPkK1OFE3PjVzPD;hQi=>
RBMECs MYXGeY5kfGmxbjDBd5NigQ>? M2S0XVXDqM7:TR?= NEXpTGcyKGh? MmrXdoV3\XK|ZYOgeIhmKGOqYX7n[ZMhcW5iWl:tNUBlcXO2cnnieZRqd25ic3XlckB4cXSqIFXNRXAuUUlidILlZZRu\W62 M4j4Z|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEG2OlUyLz5{NUSxOlY2OTxxYU6=
RBMECs NXHjUmt6TnWwY4Tpc44hSXO|YYm= MnrBOeKh|ryP NH[1R5AyKGh? MVPpcohq[mm2czD0bIUh\GWlcnXhd4VlKG:oIHHtc5VvfCCxZjDaU{0yKGmwIF3Gd{BqdmS3Y3XkJIJ6KEWPQWCtTWk> MlHFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2MU[2OVEoRjJ3NEG2OlUyRC:jPh?=
RBMECs NXj0UmVUTnWwY4Tpc44hSXO|YYm= M1rLOFXDqM7:TR?= NYnsfmsxOSCq MnvTdJJmfmWwdIOgeIhmKGmwY4LlZZNmKGmwIFjSVEBndHW6IHHjdo9{eyC2aHWgRnRDKGmwZIXj[YQh[nliIFXNRXAuUUl? M{j5S|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEG2OlUyLz5{NUSxOlY2OTxxYU6=
RBMECs NIHtPGxHfW6ldHnvckBCe3OjeR?= MX61xsDPxE1? NHe0dnUyKGh? MULwdoV3\W62czD0bIUhTU2DUD3JTU1qdmS3Y3XkJHRGTVJidnHseYUh\GWlcnXhd4U> Mm\pQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2MU[2OVEoRjJ3NEG2OlUyRC:jPh?=
RBMECs NV\LdFJ6TnWwY4Tpc44hSXO|YYm= MmrsOeKh|ryP MV[xJIg> NH\jN2xjdG:la4OgeIhmKGGldHn2ZZRqd25ib3[gVohwSS:UT1PLJIlv\HWlZXSgZpkhTU2DUD3JTS=> MnXBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2MU[2OVEoRjJ3NEG2OlUyRC:jPh?=
RBMECs Ml3rSpVv[3Srb36gRZN{[Xl? MX:wMlA2NzBwNT:1JO69VQ>? MoflNE4zPSCq NEX0NGFqdmO{ZXHz[ZMh[0GPUDDjc45k\W62cnH0bY9v MmLEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2MU[2OVEoRjJ3NEG2OlUyRC:jPh?=
ThGCs  MlKxSpVv[3Srb36gRZN{[Xl? MWmxNQKBks7:TR?= NVHvOIlWOyCq MU\pcohq[mm2czD0bIUh\W[oZXP0JI9nKEh{T{Kgc44hTUSQMjDtVm5C M13SOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEOzNFI4Lz5{NUSzN|AzPzxxYU6=
ThGCs  MVzGeY5kfGmxbjDBd5NigQ>? M4GwTVEx6oDMzszN NUDHWmoxPOLCini= NV3FOFlvcW6lcnXhd4V{KEOxQ3yyMYlv\HWlZXSgSWRPOsLiZ3Xu[UBmgHC{ZYPzbY9v NHnUZ5U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUSzN|AzPyd-MkW0N|MxOjd:L3G+
ThGCs  NYTUeGR7TnWwY4Tpc44hSXO|YYm= MonDNVDjiIsQvF2= MWS05qCLcA>? M{LrWIF2\22nboTzJGhKTjGDIHzleoVteyC2aHH0JJdmemVic4TpcZVt[XSnZDDifUBEd0OuMh?= M4XVTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEOzNFI4Lz5{NUSzN|AzPzxxYU6=
LNCaP  MkK1SpVv[3Srb36gRZN{[Xl? MkW3NVDDqM7:TR?= NIT5OYkyOiCqwrC= M1T0PGROW09? M3r6eYlv\HWlZYOgZUBlemGvYYTpZ{BqdmO{ZXHz[UBw\iCFUlXCNUBi[3Srdnn0fS=> MmTxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3NEiwPVkoRjJ3NUS4NFk6RC:jPh?=
BeWo MYTGeY5kfGmxbjDBd5NigQ>? NH[3OGYzOMLiwsXN NYrpd|hnPDkEoHi= MX\EUXNQ MnPnbY5kemWjc3XzJJRp\SCjZHjld4lwdiCxZjDUTHAuOSCvb37vZ5l1\XN? Mn[2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3Nk[3OFAoRjJ3NU[2O|QxRC:jPh?=
BeWo M1\SXGZ2dmO2aX;uJGF{e2G7 NFOzNVMzOMLiwsXN MVG0POKhcA>? NVj6b4FSTE2VTx?= M1vDTYlv[3KnYYPld{B1cGViZHnm[oVz\W62aXH0bY9vKG:oIFLlW48h[2WubIO= MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV4Nke0NEc,OjV3Nk[3OFA9N2F-
OCI-Ly18  NUjR[GY1TnWwY4Tpc44hSXO|YYm= M3nV[|QxyqEQvF2= NGjxTpEyyqCqwrC= NV\FUIhOTE2VTx?= M1T5dolv\HWlZYOgeIhmKGmwY4LlcYVvfCCxZjDjRW1RKGOxbnPlcpRz[XSrb37z MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV5NkKyNEc,OjV3N{[yNlA9N2F-
OCI-Ly1  MYrGeY5kfGmxbjDBd5NigQ>? NX7WeWJpPDEEoN88US=> MY[xxsBpyqB? MoTzSG1UVw>? M3f3cIlv\HWlZYOgeIhmKGmwY4LlcYVvfCCxZjDjRW1RKGOxbnPlcpRz[XSrb37z NGHaUHI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUW3OlIzOCd-MkW1O|YzOjB:L3G+
3T3-L1 M{X4UGZ2dmO2aX;uJGF{e2G7 M2HU[lIvPS93IN88US=> NGnGbZczPCCqwrC= M{C2WpNq\26rZnnjZY51dHliZHXjdoVie2W|IFHUS2wheHKxdHXpckBmgHC{ZYPzbY9vKGG2IHHscEBld3OnczD0[ZN1\WR? MmWwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3OUC1PVcoRjJ3NUmwOVk4RC:jPh?=
HEK293  MYnGeY5kfGmxbjDBd5NigQ>? MUK15qCKyrWP NGnIVIg{OCCvaX6= NGr0XIRqdmO{ZXHz[ZMh[0GPUDDs[ZZmdHN? NE\2[Yw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUW5NVkxQCd-MkW1PVE6ODh:L3G+
hADSCs NVrNVlJ{TnWwY4Tpc44hSXO|YYm= Mly4OgKBkcL3TR?= NFvDVlE{OCCvaX6= NGrKPXhqdmO{ZXHz[ZMh[0GPUDDs[ZZmdHN? MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV7MUmwPEc,OjV3OUG5NFg9N2F-
SH-SY5Y  NXnOTWU4TnWwY4Tpc44hSXO|YYm= NYjQSmJNOTEEoN88US=> NWHGe5h6OcLiaNMg M2rtWolv[3KnYYPld{BCT0NzIH3SUmEhdGW4ZXy= NUL5[5lyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1PVc1OzNpPkK1OVk4PDN|PD;hQi=>
SH-SY5Y  NIflO4tHfW6ldHnvckBCe3OjeR?= NWfjblREOTEEoN88US=> MXKxxsBpyqB? NFvZbm1qdmO{ZXHz[ZMhVFWFIHHjeIl3cXS7 M4P1PVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUm3OFM{Lz5{NUW5O|Q{OzxxYU6=
UACC-647  NX\kbXVSTnWwY4Tpc44hSXO|YYm= NIrB[FEyOMLizszN MnLENVUhdWmw Mom0SG1UVw>? NVnyNYZocW6lcnXhd4V{KGWHRkKgdIhwe3Cqb4L5cIF1cW:wIHzleoVte8Li NF;mbJE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUewN|AzPSd-MkW3NFMxOjV:L3G+
UACC-647  M{P3cGZ2dmO2aX;uJGF{e2G7 NVTCbJBCOTEEoN88US=> NXu2XIRXOTVibXnu M4iwV2ROW09? NHPP[4JqdmirYnn0d{BGWkticHjvd5Bpd3K7bHH0bY9v NH\HR3g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUewN|AzPSd-MkW3NFMxOjV:L3G+
UACC-647  NV\UN2V[TnWwY4Tpc44hSXO|YYm= M3f2dWROW09? NXr3WIpydGWjZIOgeI8h[SC{aYPlJIlvKGODTWCgcIV3\Wy|IDjFR|UxyqB;wrCyNE4{QcLizszNLS=> MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTdyM{CyOUc,OjV5MEOwNlU9N2F-
SC MX\GeY5kfGmxbjDBd5NigQ>? MoL5NE42KM7:TR?= NHqxdZY4OiCq NXHyUHNXcW6lcnXhd4V{KGKxdHigT5JwgC1{MDDhcoQhVzFiZYjwdoV{e2mxbjDpckBigG:wLYLlcIF1\WRiU1PzJIJ2fCCxbnz5JGtzd3hvMkFCpC=> NVexTph3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3NFU5PzRpPkK1O|A2QDd2PD;hQi=>
SC NGDpc|FHfW6ldHnvckBCe3OjeR?= MUewMlUh|ryP M1\oZ|I1KGh? MVLtbY1q[2u|IITo[UBm\m[nY4Sgc4Yh[0GPUDDhcoFtd2e|IH;uJG8yKGGwZDDNRnAh\XiycnXzd4lwdg>? NEPMNnI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUewOVg4PCd-MkW3NFU5PzR:L3G+
oocytes MnnYSpVv[3Srb36gRZN{[Xl? NUDGRoE5PSEQvF2= NI[4[nYzPCCq M172fYF1fGWwdXH0[ZMhemhvaX7zeYxqdiCjY4Tpc44hd25ib3;jfZRmKEeYQlSgd4lodmmoaXPhcpRtgcLi MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTdyN{i1OEc,OjV5MEe4OVQ9N2F-
BeWo NIrn[2lHfW6ldHnvckBCe3OjeR?= NYO3ZWJPOTEkgJtOwG3DqA>? NGHIOYE4OiCq MnnVSG1UVw>? NVjIVWE3dWWmaXH0[ZMhSmWZbzDj[YxtKGSrZn\ldoVvfGmjdHnvci=> NIDNe|k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUexN|QzPSd-MkW3NVM1OjV:L3G+
GH3 MnXtSpVv[3Srb36gRZN{[Xl? MV[xxsDPxE1? NULSfW5DPi2q NIq2fYdqdmS3Y3XzJHBTVCCjbnSgRo1idDFuIHL1eEBvd3RiQ3zvZ4stKG2UTlGg[ZhxemW|c3nvci=> NHXiW2s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUeyO|AyQCd-MkW3NlcxOTh:L3G+
GH3 M{LJfGZ2dmO2aX;uJGF{e2G7 NVK1PWh6OcLizszN Mo[5Ok1p M13PZ4F1fGWwdXH0[ZMhfGinIHPvdpJmdGG2aX;uJIJmfHenZX6gVHJNKGGwZDDCcYFtOSCneIDy[ZN{cW:w NWjhWWNKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3NlcxOThpPkK1O|I4ODF6PD;hQi=>
PC12 MVzGeY5kfGmxbjDBd5NigQ>? MX6yOeKh|ryP NILNdIw1QCCq M125XIFkfGm4YYTld{BkSU2S M{WzXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{[5N|A2Lz5{NUe2PVMxPTxxYU6=
BAECs M3rNV2Z2dmO2aX;uJGF{e2G7 M1jZS|I2KM7:TR?= NF70PHczPCCq NV\YU4Jl\W6qYX7j[ZMhfGinIHHjeIl3[XSrb36gc4YhWFCDUt8xJIJ6KDVizszNJJJme3[ncnH0do9tNCCWNFjTMEBweiB2LWDBVC=> M2\wN|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{m4PFI3Lz5{NUe5PFgzPjxxYU6=
GLUTag  M3jBUmZ2dmO2aX;uJGF{e2G7 NUTNZ4FOOTEkgJpCuW0> M1fRNVQhcA>? M{LxNYlv[3KnYYPld{B1cGVicFPSSWIhdGW4ZXzzJJdqfGhidHjlJGlDVVh? MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh|Mk[zNUc,OjV6M{K2N|E9N2F-
GLUTag  NVLwXZJsTnWwY4Tpc44hSXO|YYm= NHq4SnEyOOLCidM1US=> MlroNE8zNzRiaB?= NXPPXpJKe3SrbYXsZZRmeyCJTGCtNUB{\WO{ZYTpc44h[2:2cnXheIVlKHerdHigTWJOYA>? M2fvflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEOyOlMyLz5{NUizNlY{OTxxYU6=
PBMC MoPvSpVv[3Srb36gRZN{[Xl? NVvY[JVoPTEEoN88US=> NWLCc3c3OjUEoHlCpC=> NEO2VYpqdmirYnn0d{B1cGViaX7jdoVie2WmIIPlZ5JmfGmxbjDv[kBVVkZiaX7keYNm\CCkeTD0bIUhTFCH MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh4NkC3PUc,OjV6Nk[wO|k9N2F-
H295R  NYXZbndxTnWwY4Tpc44hSXO|YYm= M{PMbVExyqEQvF2= MVi0POKhcA>? MWrpcoNz\WG|ZYOgd5Rmem:rZDDt[ZRi[m:uaYTld{BqdiC2aHWgZY5lem:pZX6sJI1qdmW{YXzvMUBidmRiZ3z1Z49kd3K2aXPvbYQheGG2aIfhfZM> MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh4OUW1Okc,OjV6Nkm1OVY9N2F-
3T3-L1 preadipocytes MULGeY5kfGmxbjDBd5NigQ>? MVexNEDPxE4EoB?= MoLSNVIhcA>? NUDTUZkxcW6mdXPld{BEWkWEIIDoc5NxcG:{eXzheIlwdiCjbnSgR{9GSlEQsjDlfJBz\XO|aX;u MkT6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7MkiwOVgoRjJ3OUK4NFU5RC:jPh?=
PCCL3 NGPDRZRHfW6ldHnvckBCe3OjeR?= M3:xOVExKML3TR?= Ml;RNlQhcA>? NUTjT2M4\W6qYX7j[ZMhTHWReEKgdJJwdW:2ZYKgeJJidnOlcnnweIlwdiCjY4Tpeol1gcLi4pEL M4P6bFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OU[wPVU3Lz5{NUm2NFk2PjxxYU6=
SCG MYrGeY5kfGmxbjDBd5NigQ>? NFvMZncyODBizszNxsA> NVPIbpB7TE2VTx?= NInXfoJz\WS3Y3XzJJRp\SCneHPpeIFjcWyrdImgc4YhW0OJIH7leZJwdnN? MknuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7NkKxN|IoRjJ3OU[yNVMzRC:jPh?=
HEK-293 NUTtelhVTnWwY4Tpc44hSXO|YYm= M4rKNlM2KM7:TdMg MUXEUXNQ MWPpcoR2[2W|IHGgZ49ve3CrY4XveZMh6oDeaX7hZ5RqfmG2aX;u5qCeKG:oIITo[UBMfjJwMTDjeZJz\W62 M2\LUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OU[yNVMzLz5{NUm2NlE{OjxxYU6=
SCG MVLGeY5kfGmxbjDBd5NigQ>? M2jHcFIxKM7:TdMg NHXkOZNFVVOR M2nOPZJmfmW{c3nicJkhe3WycILld5NmeyCLS2[ge4l1cCCjIFnDOVAhd2ZiMkSuOEDPxE1? NV7XS4JORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5OlIyOzJpPkK1PVYzOTN{PD;hQi=>
PC-3 M3rORWNmdGxiVnnhZoltcXS7IFHzd4F6 MUG0NEDDvU1? NXjOXmw2OjRxNEivO|IhcA>? Mo\HSG1UVw>? NVj1V3FP\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJRqdWViZHXw[Y5l\W62bIm= MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB{M{izOkc,OjZyMkO4N|Y9N2F-
PC-3 NETjUlJHfW6ldHnvckBCe3OjeR?= MmjjOFAhyrWP Mk\ENkBp NX;YSpJ5TE2VTx?= M3Hqc4xm[WS|IITvJHBROkFiYXP0bZZifGmxbh?= NE\veGU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkCyN|g{Pid-Mk[wNlM5OzZ:L3G+
SH-SY5Y MoXNSpVv[3Srb36gRZN{[Xl? M{nNVVMxKM7:TR?= NXPFZ4JvOzBibXnu MlLxSG1UVw>? Mle0d4lodmmoaXPhcpRtgSCrbnPy[YF{\XNidHjlJIFkfGm4YYTpc44hd2ZiUFvB M2LZ[|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEK1NVM4Lz5{NkCyOVE{PzxxYU6=
EndoC-βH1 NXz5VVZ[TnWwY4Tpc44hSXO|YYm= MYi1xsDPxE1? NVHFWlFCOSCq MWPs[YFleyC2bzDhJJN1em:wZzDjRW1RKGmwY4LlZZNm MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB{OEW2Nkc,OjZyMki1OlI9N2F-
EndoC-βH1 M4nsbGZ2dmO2aX;uJGF{e2G7 M2jkPVXDqM7:TR?= MkjmNUBp M1mwRpBwfGWwdHnheIV{KGeudXPvd4UucW6mdXPl[EBqdnO3bHnuJJNm[3KndHnvckBqdiC2aHWgdJJme2WwY3Wgc4Yh\2y3Y3;z[S=> MoGyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyMki1OlIoRjJ4MEK4OVYzRC:jPh?=
RBMECs M17FUmZ2dmO2aX;uJGF{e2G7 NEXFdGY2yqEQvF2= M{nwclEhcA>? M3vpe4lvcGmkaYTzJGVOSVBvSVmtbY5lfWOnZDDpcoFkfGm4YYTpc44hd2ZiUnHwNeKh NHjtVo49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC0OFY3Oyd-Mk[wOFQ3PjN:L3G+
AML-12  NYTmcZBzTnWwY4Tpc44hSXO|YYm= NE[1[4YzOCEQvF2= NIOyeng{KGh? M17ycYlv\HWlZYOgeIhmKGSncHjvd5Bpd3K7bHH0bY9vKG:oIFPSWGMzyqB? NUflRXYzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wOFg6QDVpPkK2NFQ5QTh3PD;hQi=>
AML-12  NHTtZZlHfW6ldHnvckBCe3OjeR?= NUPN[4J[OjBizszN M4q1OlMhcA>? M1TSd5VxNXKnZ4XsZZRme8LiUHfjNYEtyqCSZYDjb{wh[W6mwrDHOpBkyqCvUl7BJIxmfmWucx?= NYS1TFA5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wOFg6QDVpPkK2NFQ5QTh3PD;hQi=>
AML-12  NEjvdoJHfW6ldHnvckBCe3OjeR?= NHrRZZIzOCEQvF2= NYm5dm1zOS16IHi= MoO1bY5kemWjc3XzJIdtfWOxc3WgdJJw\HWldHnvci=> M1XDOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MES4PVg2Lz5{NkC0PFk5PTxxYU6=
AML-12  NIX6Vm5HfW6ldHnvckBCe3OjeR?= NV3nPZllOjBizszN Mn;oN{Bp NWLEflVTfXC{ZXf1cIF1\XNidHjlJJBpd3OyaH;yfYxifGmxbjDs[ZZmdHNiYYSgWIhzNTRzMTDhcoQhW2W{LUS5Ny=> MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB2OEm4OUc,OjZyNEi5PFU9N2F-
Caco-2  M3qyR2Z2dmO2aX;uJGF{e2G7 Mn3uNE4yNzFxMUCg{txO Mki4NlQhcA>? NWDWU41IcW6lcnXhd4V{KE2UUEKgdJJwfGWrbjDs[ZZmdA>? MkS3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyNEmxNFIoRjJ4MES5NVAzRC:jPh?=
Caco-2  MU\GeY5kfGmxbjDBd5NigQ>? NHTsW2UxNjFxMT:xNEDPxE1? M{\jW|IxyqCvaX6= NVvoXI5TcW6mdXPld{BiKGSxc3Wt[IVx\W6mZX70JIlv[3KnYYPlJIlvKGmwdILhZ4VtdHWuYYKgZ2FOWCCuZY\lcJM> MlPiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyNEmxNFIoRjJ4MES5NVAzRC:jPh?=
bovine oocytes NETMOXlHfW6ldHnvckBCe3OjeR?= MmLiNVAxyqEQvF2= NGHmT3UyOsLiaB?= MX3pcohq[mm2czD0bIUh\W[oZXP0JI9nKE6SUFGgZY5lN2:{IF7QVGMhfG9ic4TpcZVt[XSnIILld5VueHSrb36gc4YhdWWrb4Ppdy=> Mk\xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyNUG2NVEoRjJ4MEWxOlEyRC:jPh?=
BeWo  MonkSpVv[3Srb36gRZN{[Xl? M1G4RVI26oDLzszN M3j4W|I1NzR6L{eyJIg> NYrGeoRydGWjZIOgeI8h[W5iaX7jdoVie2ViaX6geIhmKGW6cILld5Nqd25ib3[gc5Rp\XJiZoXzbY9vKG2jcnvldpM> NIWwPJg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC1N|U1QSd-Mk[wOVM2PDl:L3G+
Spinal cords  NF\PZ4JHfW6ldHnvckBCe3OjeR?= NWPSWJg{OcLizszN NWjsVJp7OzBibXnu MVTzeIlufWyjdHXzJINCVVBibHX2[Yx{ MnO3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzMk[5NlYoRjJ4MUK2PVI3RC:jPh?=
MDCK  MULGeY5kfGmxbjDBd5NigQ>? MmHJNVAhyrWP MojoNlQhcA>? NW\oR|Z6TE2VTx?= M1rSPYlvcGmkaYTzJJRp\SCrbnPy[YF{\WRiZYjwdoV{e2mxbjDv[kBHViClYYXz[YQh[nliVFfGMe6zOQ>? NYnBfYpqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yNFI{PTJpPkK2NlAzOzV{PD;hQi=>
MDCK  NGC1dVFHfW6ldHnvckBCe3OjeR?= NV2wUGs5OTBiwsXN MUKyOEBp MlLESG1UVw>? MYL1dJJm\3WuYYTld{B1cGViZYjwdoV{e2mxbjDv[kBVT0ZvzsKxJIFv\CCFVFfGxsA> NVuxPG1wRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yNFI{PTJpPkK2NlAzOzV{PD;hQi=>
RPMI 8226 MmOyR4VtdCCYaXHibYxqfHliQYPzZZk> M4[3WFAuOTByIN88US=> MmLMO|LjiImq NGTHUlVqdmS3Y3XzJINmdGxiZHXheIgh\G:|ZTDk[ZBmdmSnboTsfS=> MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjNyNk[yOEc,OjZ|ME[2NlQ9N2F-
H929 M{H3U2NmdGxiVnnhZoltcXS7IFHzd4F6 M3zPOVAuOTByIN88US=> NXToZlBrPzMkgJno Mnu0bY5lfWOnczDj[YxtKGSnYYToJIRwe2ViZHXw[Y5l\W62bIm= NX\lOmVoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zNFY3OjRpPkK2N|A3PjJ2PD;hQi=>
U266 NGfxfGtE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M{G2ZlAuOTByIN88US=> MWK3NwKBkWh? MlPvbY5lfWOnczDj[YxtKGSnYYToJIRwe2ViZHXw[Y5l\W62bIm= NHOxTpk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkOwOlYzPCd-Mk[zNFY3OjR:L3G+
OPM-2 MXTD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MV:wMVExOCEQvF2= M2\u[Vcz6oDLaB?= NEDqWY5qdmS3Y3XzJINmdGxiZHXheIgh\G:|ZTDk[ZBmdmSnboTsfS=> M4ricVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{C2OlI1Lz5{NkOwOlYzPDxxYU6=
INA-6 NEXvbVhE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MnXpNE0yODBizszN M4jpS|cz6oDLaB?= NXu3OJppcW6mdXPld{Bk\WyuIHTlZZRpKGSxc3Wg[IVx\W6mZX70cJk> MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjNyNk[yOEc,OjZ|ME[2NlQ9N2F-
RBMECs  MljrSpVv[3Srb36gRZN{[Xl? MUS1xsDPxE1? MlzmNeKhcA>? M3j3NIJtd2OtczD0bIUhWmGlMTDpcoFkfGm4YYTpc44hcW6mdXPl[EBjgSCHTVHQMWlK NF;mNpA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkO1PFA{QSd-Mk[zOVgxOzl:L3G+
Mo-DCs NX3zUotZTnWwY4Tpc44hSXO|YYm= NUW0eVhTPTBizszN Mkj4NlTjiImq MkLPdJJwdW:2ZYOgTWwuOjNicILv[JVkfGmxbjDpckB1cGVic4Xw[ZJv[XSjboSgc4Yhgnmvb4PhckB{fGmvdXzheIVlKE2xLVTDd:Kh NI\yWYU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkSxNlk1QCd-Mk[0NVI6PDh:L3G+
HEK293 NV7ZbJRYTnWwY4Tpc44hSXO|YYm= Mm\NNVAh|ryP MnHCOkBp NYTVe4ZVcW6lcnXhd4V{KHCqb4PwbI9zgWyjdHnvckBw\iCxdnXy[ZhxemW|c3XkJGtNUEx|IHH0JHM1OzN? M3f5OlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NEO1OFk5Lz5{NkSzOVQ6QDxxYU6=
ASK MmjNSpVv[3Srb36gZZN{[Xl? MnfxNUBpeg>? MmftQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2OU[0NUc,Ojh2OU[0NVww[T5?
Vero E6 MV;BcpRqfmm{YXygZZN{[Xl? M4nNT|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5Nk[zOVM6Lz5zN{[2N|U{QTxxYU6=
epithelial cells NXfPcIlMTnWwY4Tpc44h[XO|YYm= MWqxJJVO NVP3cnpxPCxiNjygZY5lKDhiZHH5dy=> NWeyXXFLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm5OlY4QDlpPkG5PVY3Pzh7PD;hQi=>
HepG2 (DPX-2) NHnsbVRHfW6ldHnvckBie3OjeR?= Mln1NlQhcHK| NWn4U|NjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC5OlYxPDNpPkKwPVY3ODR|PD;hQi=>
HepG2 NIXnSGFHfW6ldHnvckBie3OjeR?= NU[1cGJDOjRiaILz NYHUeJc1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC5OlYxPDNpPkKwPVY3ODR|PD;hQi=>
HepG2 (DPX-2) NVjDc4U2TnWwY4Tpc44h[XO|YYm= MYiyOEBpenN? NGXrVm49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEm2OlA1Oyd-MkC5OlYxPDN:L3G+
HEK293T MWjGeY5kfGmxbjDhd5NigQ>? MWWxNEB2VQ>? MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN6N{OyOUc,OjR|OEezNlU9N2F-
HEK293 NVnSb5BGTnWwY4Tpc44h[XO|YYm= NYPpcJlYOTBidV2= NYfvOGZ6OTZiaILz NXyzdWVJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[0N|U2OTJpPkK2OFM2PTF{PD;hQi=>
MCF7 NHTJToZEgXSxdH;4bYNqfHliYYPzZZk> NGe2cXc1QCCqcoO= MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDh|OE[5Nkc,Ojh6M{i2PVI9N2F-
HEK293 MVnGeY5kfGmxbjDhd5NigQ>? NV\BWlFOOzBibXnudy=> M1H4clxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMEC2NVc3Lz5|MECwOlE4PjxxYU6=

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ
Methods Test Index PMID
Western blot
cleaved caspase-3 / caspase-3; 

PubMed: 30863177     


Toledo, NK-92, RL, and Farage cells were treated with 30 μM of forskolin for 48 hours, then the cells were harvested for Western blotting to assess the expression of total or cleaved caspase-3

cleaved caspase-9 / caspase-9 ; 

PubMed: 30863177     


Toledo, NK-92, RL, and Farage cells were treated with 30 μM of forskolin for 48 hours, then the cells were harvested for Western blotting to assess the expression of total or cleaved caspase-9.

β-catenin; 

PubMed: 30863177     


(A, B) The protein expression of cytoplasmic and nuclear β-catenin in Toledo and NK-92 cells in the presence of 0, 10, 20, or 40 μM forskolin was detected by Western blotting.

c-myc / Cyclin D1; 

PubMed: 30863177     


(C, D) Western blotting analysis of the total protein expression of c-myc and cyclin D1 influenced by 0, 10, 20, or 40 μM of forskolin in Toledo and NK-92 cells (n=3, *P<0.05, forskolin group vs control group).

pS6K1 / S6K1 / pCREB / CREB; 

PubMed: 31112131     


Forskolin inhibits mTORC1 in multiple cell lines. PC3, LNcap/AR, H1299, H1944, MDA-MB-231, MEF, HAP1, COS7, HeLa, MIA Paca-2, and PANC-1 were treated with or without 10 μM forskolin for 1 h and mTORC1 activity, CREB phosphorylation, and loading controls were analyzed.

p-JNK / JNK / P-p38 / p38; 

PubMed: 20070884     


L929 cells were pretreated with forskolin (10 μM) for various times as indicated, followed by stimulation with or without 10 ng/ml TNF-α for 15 min.

30863177 31112131 20070884
Immunofluorescence
5hmC; 

PubMed: 29239726     


Schwann cells were treated with forskolin (10 μM) for 3 hr followed by washout. 5hmC induction was detected at of 0, 3, and 24 hr time points following treatment. Cells continuously treated with forskolin (5, 10 μM) for 24 hr showed comparable 5hmC levels. Scale bar = 20 μm. 

Fe(II); 

PubMed: 29239726     


AMP (100 mM) treatment for 4 hr did not induce labile Fe(II) while AC activators (forskolin (100 mM), bicarbonate (50 mM)) and PDE inhibitors (caffeine (100 mM), IBMX (100 mM)) increased labile Fe(II) detected by Trx-Puro probes.

CYP17A1 / CYP21A2; 

PubMed: 25334044     


H295R cells were treated with 8-Br-cAMP or forskolin for 48 h under growth conditions, and fixed with 4% paraformaldehyde. (A) Immunostaining for CYP17A1. Red staining shows the anti-CYP17A1 antibody and blue staining shows DAPI (cell nuclei). (B) Immunostaining for CYP21A2. Red staining shows the anti-CYP21A2 antibody and blue staining shows DAPI (cell nuclei). Scale bars represent 100 µm.

29239726 25334044
Growth inhibition assay
Cell viability; 

PubMed: 30863177     


(C) MTT assay was conducted to test the cell growth after Toledo cells were administered 0, 20, 40, 80, or 160 μM of forskolin for 1, 2, 3, 4, 5, or 6 days. (D) Toledo cells were administered 0, 20, 40, 80, or 160 μM of forskolin for 48 hours, then MTT assay was used to evaluate the IC50 of forskolin. (F) MTT assay was conducted to test the cell growth after NK-92 cells were administered 0, 20, 40, 80, or 160 μM of forskolin for 1, 2, 3, 4, 5, or 6 days. (G) NK-92 cells were administered 0, 20, 40, 80, or 160 μM of forskolin for 48 hours, then MTT assay was used to evaluate the IC50of forskolin. 

30863177

お薦めの試験操作(参考用のみ)

溶解度 (25°C)

体外 DMSO 82 mg/mL (199.75 mM)
Water Insoluble
Ethanol ''37 mg/mL ''37

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 410.5
化学式

C22H34O7

CAS No. 66575-29-9
Storage powder
in solvent
別名 Forskolin, HL 362, Coleonol
Smiles CC(=O)OC1C(C2C(CCC(C2(C3(C1(OC(CC3=O)(C)C=C)C)O)C)O)(C)C)O

投与溶媒組成計算器(クリア溶液)

ステップ1:実験データを入力してください。(実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します)
投与量 mg/kg 動物平均体重 g 投与体積(動物毎) ul 動物数
ステップ2:投与溶媒の組成を入力してください。(ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください)
% DMSO % % Tween 80 % ddH2O
計算リセット

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04254705 Not yet recruiting Procedure: Rectal Biopsy Cystic Fibrosis Universitaire Ziekenhuizen Leuven|Vertex Pharmaceuticals Incorporated|KU Leuven|University of Lisbon March 1 2020 Not Applicable
NCT02807415 Completed Drug: Lumacaftor plus Ivacaftor Cystic Fibrosis Hannover Medical School|Heidelberg University|University of Giessen June 1 2016 --
NCT02586883 Completed Other: bronchial ddp test Idiopathic Dilation of the Bronchi Assistance Publique - Hôpitaux de Paris March 29 2016 Not Applicable
NCT03652090 Completed Procedure: cell sampling Cystic Fibrosis Institut National de la Santé Et de la Recherche Médicale France|ABCF2 September 1 2010 --

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

cAMPシグナル伝達経路

Tags: Colforsin を買う | Colforsin ic50 | Colforsin 供給者 | Colforsin を購入する | Colforsin 費用 | Colforsin 生産者 | オーダーColforsin | Colforsin 化学構造 | Colforsin 分子量 | Colforsin 代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID